| Name | Title | Contact Details |
|---|---|---|
Dan Jamieson |
Associate Director Enterprise Architecture | Profile |
Diana Atwell |
Associate Director, Information Systems | Profile |
Passage Bio was launched with the vision to be a first in class fully-integrated biotech company developing life transforming AAV-delivered in vivo therapeutics for the treatment of rare CNS diseases. In collaboration with the University of Pennsylvania Gene Therapy Program, Philadelphia-based Passage Bio plans to advance a portfolio of 5 rare disease indications in the neuro/CNS genetic space through IND-enabling studies using best-in-class AAV technology and know-how. Subsequently, Passage Bio will be responsible for all clinical development and will collaborate with Penn`s Orphan Disease Center to support these efforts.
Biothera, the Immune Health Company is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Santen Inc. is a Napa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Muse bio is transforming genome engineering by enabling, for the first time, high throughput massively-multiplexed CRISPR editing of proteins, pathways, and genomes. Through our powerful bioinformatics and novel molecular approach, ForgeCraft generates low-cost libraries of thousands of designer protein, pathway, or genome variants each with specifically defined, trackable mutations. This allows the impact of specific changes to be determined through rapid selection and high throughput screening allowing research timelines and costs to be reduced.
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead`s pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.